Comparative Pharmacology
Head-to-head clinical analysis: ACCUNEB versus BRICANYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACCUNEB versus BRICANYL.
ACCUNEB vs BRICANYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
None Documented
None Documented
2-5 hours (procainamide); 6-8 hours (N-acetylprocainamide); prolonged in renal impairment (up to 20 hours)
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Renal: ~70% as unchanged drug and active metabolite (N-acetylprocainamide) within 24 hours; biliary/fecal: minimal (<5%)
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Category C
Category C
Beta-2 Agonist
Beta-2 Agonist